Life Science Tools & Services – 2024
Date 14 mayo 2024
Type Investment Banking
Life Science Tools and Services (LSTS) sector is showing early signs of a shift towards a more positive outlook, with short-term demand drivers representing the first hint of a recovery. As funding and inventory levels normalize, it is anticipated that demand for bioprocess equipment and consumables will return to long-term trends. Companies are anticipating to see growth return in 2H 2024.
New legislation and regulations have emerged in the LSTS sector in late 2023 and early 2024 that could have a major impact on the industry. The BIOSECURE Act and a revised regulatory framework for lab-developed tests creates uncertainty for many subsectors that will need to be navigated.
Life Science Tools and Services sector is supported by long term trends such as increasing demand for new therapies driven by several recent successful new drug applications. New modalities, such as antibody-drug conjugates (ADCs), are experiencing increased M&A activity, and Artificial Intelligence / Machine Learning (AI/ML) is becoming a central focus for investment by biopharmaceutical companies with the potential to enhance productivity.